Compugen Ltd
CGEN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001119774
In the last 90 days, Compugen Ltd insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $30.3M in total; ARK Invest is the only superinvestor holding it.
Holders of 5% or more of CGEN
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Compugen Ltd, largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Compugen Ltd on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
1 Schedule 13D or 13G filing on Compugen Ltd, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 14, 20254:10 PM ET | Bristol Myers Squibb Co | 13G/A | 2.06%1.84M shares | –Below 5% | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Compugen Ltd shares.
No Form 144 notices for Compugen Ltd are on file.